Literature DB >> 6034625

Late results of long-term intermittent chemotherapy of advanced, murine tuberculosis: limits of the murine model.

F Grumbach, G Canetti, J Grosset, M le Lirzin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1967        PMID： 6034625     DOI： 10.1016/s0041-3879(67)80047-3

Source DB:  PubMed          Journal:  Tubercle        ISSN： 0041-3879


× No keyword cloud information.
  9 in total

1.  Intermittent treatment regimens in pulmonary tuberculosis.

Authors:  M Zierski
Journal:  Lung       Date:  1979       Impact factor: 2.584

Review 2.  General considerations in intermittent drug therapy of pulmonary tuberculosis.

Authors:  W Fox
Journal:  Postgrad Med J       Date:  1971-11       Impact factor: 2.401

3.  Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice.

Authors:  N Lounis; A Bentoucha; C Truffot-Pernot; B Ji; R J O'Brien; A Vernon; G Roscigno; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

4.  Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models.

Authors:  Si-Yang Li; Scott M Irwin; Paul J Converse; Khisi E Mdluli; Anne J Lenaerts; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2015-04-27       Impact factor: 5.191

5.  Short course intermittent chemotherapy in childhood tuberculosis.

Authors:  A Göçmen; U Ozçelic; N Kiper; M Toppare; S Kaya; R Cengizlier; F Cetinkaya
Journal:  Infection       Date:  1993 Sep-Oct       Impact factor: 3.553

6.  [Cooperative controlled trial of thiocarlide (DATC), PAS and bedrest alone in short-term single-drug treatment in retreated cavitary pulmonary tuberculosis].

Authors: 
Journal:  Beitr Klin Erforsch Tuberk Lungenkr       Date:  1969

Review 7.  Drug therapy in spinal tuberculosis.

Authors:  S Rajasekaran; Gaurav Khandelwal
Journal:  Eur Spine J       Date:  2012-05-12       Impact factor: 3.134

Review 8.  Animals devoid of pulmonary system as infection models in the study of lung bacterial pathogens.

Authors:  Yamilé López Hernández; Daniel Yero; Juan M Pinos-Rodríguez; Isidre Gibert
Journal:  Front Microbiol       Date:  2015-02-04       Impact factor: 5.640

Review 9.  One Size Fits All? Not in In Vivo Modeling of Tuberculosis Chemotherapeutics.

Authors:  Hee-Jeong Yang; Decheng Wang; Xin Wen; Danielle M Weiner; Laura E Via
Journal:  Front Cell Infect Microbiol       Date:  2021-03-16       Impact factor: 5.293
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.